Dokument: Prevalence of and factors associated with a treatment delay due to the COVID-19 pandemic in patients with gastrointestinal cancer in Europe
| Titel: | Prevalence of and factors associated with a treatment delay due to the COVID-19 pandemic in patients with gastrointestinal cancer in Europe | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68740 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250221-093604-3 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Roderburg, Christoph [Autor] Loosen, Sven H. [Autor] Leyh, Catherine [Autor] Joerdens, Markus S. [Autor] Mohr, Raphael [Autor] Luedde, Tom [Autor] Alymova, Svetlana [Autor] Klein, Isabel [Autor] Kostev, Karel [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Colorectal cancer, Malignancy, SARS-CoV-2, Pandemic, Tumor | |||||||
| Beschreibung: | Background
Recent studies have raised the issue of delayed cancer care during the COVID-19 pandemic, but the extent of delays and cancellations in cancer treatment, screening and diagnosis varied widely by geographic region and study design, highlighting the need for further research. Methods We used the Oncology Dynamics (OD) database featuring data from a cross-sectional, partially retrospective survey to analyze treatment delays in 30,171 GI cancer patients from five European countries (Germany, France, UK, Spain, and Italy). Risk factors for treatment delays were identified using multivariable logistic regression models. Results Treatment delays were documented in 1342 (4.5%) of the study patients, with most patients having a delay of less than 3 months (3.2%). We observed decisive differences of treatment delay in relation to geographical, healthcare- and patient-related factors. Treatment delay was highest in France (6.7%) and Italy (6.5%) and lowest in Spain (1.9%, p < 0.001). 5.9% of patients treated at general hospitals but only 1.9% of those treated by office-based physicians experienced treatment delays (p < 0.001). Moreover, the difference between lines of therapy was highly significant and ranged from 7.2% for early-stage patients in primary therapy to 2.6% in advanced/metastatic cancer patients receiving 4th or later line therapy (p < 0.001). Finally, the proportion of cases with delayed treatments increased from 3.5% in asymptomatic patients (ECOG 0) to 9.9% in bedridden patients (ECOG IV, p < 0.001). Results were confirmed in multivariable logistic regression models. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Roderburg, C., Loosen, S. H., Leyh, C., Jördens, M. S., Mohr, R., Lüdde, T., Alymova, S., Klein, I., & Kostev, K. (2023). Prevalence of and factors associated with a treatment delay due to the COVID-19 pandemic in patients with gastrointestinal cancer in Europe. Journal of Cancer Research and Clinical Oncology, 149(13), 11849–11856. https://doi.org/10.1007/s00432-023-05062-w | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 21.02.2025 | |||||||
| Dateien geändert am: | 21.02.2025 |
